Skip to main content

Potential to Redefine Dry Eye Disease Drug Therapies with EyeSol®

Our products target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials

Dry eye disease (DED) is a global, multifactorial and complex disease of the ocular surface. Currently more than 13 million Europeans and 17 million Americans are diagnosed with DED.

The majority of diagnosed DED patients fail to get a satisfactory response with current treatments. Over 60% of patients using currently approved drug therapies in the U.S. discontinue their treatment within 12 months of initiation. In particular, local intolerabilities and lack of efficacy are considered to be key reasons for the high discontinuation rates.

EyeSol®, Novaliq’s unique and proprietary water-free technology, opens completely new and intriguing opportunities to target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials.

Medicinal products

CyclASol® and NOV03 address two distinct root causes of dry eye disease. The mode-of-actions are not competitive as they target two different underlying drivers of the disease: inflammation and abnormal lipid layer due to Meibomian gland dysfunction.

NOV03 (perfluorohexyloctane) is a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

As a unique tear film stabilizer it is designed to prevent excessive tear evaporation and restore tear balance in patients with evaporative DED. Evaporative DED occurs due to Meibomian gland dysfunction leading to a deficient lipid layer and increased evaporation rates. The product was regulatory approved by U.S. Food and Drug Administration (FDA) as Miebo™ in May, 2023 and by the China National Medical Products Administration (NMPA) as Heng Qin™ in July 2025.

CyclASol® (cyclosporine ophthalmic solution 0.1%) is recognized to be potentially the most powerful and comfortable anti-inflammatory DED therapy with high responder rates, rapid onset and unique efficacy on corneal damages combined with high patient satisfaction and comfort. The product was regulatory approved by U.S. Food and Drug Administration (FDA) as Vevye® in May 2023 and in the European Union as Vevizye® in September 2024. In the meantime, it has also obtained approval in New Zealand, Australia, UK and Switzerland.

Today anti-inflammatory therapeutic options are standard for care in DED. Inflammation is the key underlying driver of the disease as chronic immunologic processes have a pivotal role in the pathology of dry eye. The chronic inflammatory nature of DED also causes progressive corneal surface damage. Corneal surface damage can negatively affect visual function and any refractory eye care outcome in particular in cataract or refractive patients where dry eye is common. It addresses the medical need for a therapy that can rapidly and reliably repair corneal surface damage secondary to DED with better comfort.

CyclASol®

CyclASol® has the potential to change the way eye care practitioners treat patients with dry eye disease
read more

NOV03

Is the first drug with novel mechanism of action developed to treat the signs and symptoms of evaporative dry eye disease associated with Meibomian gland dysfunction in a highly effective way

read more

Novaliq products

NovaTears®

NovaTears® is the first water-free eye drop based on EyeSol® developed for the treatment of dry eye. Novatears® is CE certified since 2013 and successfully commercialized in Australia/New Zealand and in Europe by our partners.

NovaTears® is clinically validated by significant improvement in signs and symptoms in evaporative dry eye disease and MGD patients (4 clinical trials).

NovaTears®+Omega-3

NovaTears®+Omega-3 eye-drops is a line extension of Novaliq’s existing CE-marked product NovaTears® containing 0,2% Omega-3 fatty acids.

The clear, multi-dose solution is stable at ambient temperatures and intended for use as an ocular lubricant in conditions involving instability of the tear film leading to dry eye syndrome

Novaliq transformed Dry Eye Disease therapies – now expanding into Retina.

Our water-free technology, opens completely new and intriguing opportunities to cure, relief and prevent diseases in various indications.

Novaliq’s Pipeline: Topical Therapies based on EyeSol

Anterior eye diseases (Dry Eye Disease)

EyeSol® Product Indication Preclinics Phase II Phase III NDA/MAA Milestone(s)
Vevizye® / Vevye®
(ciclosporin ophthalmic solution, 0.1%) 		Dry eye disease
(inflammatory)
Approved & partnered in: European Union, USA, UK, Australia, New Zealand
 
 Approval in China Expansion to other ROW countries
Miebo® / Heng Qin®
(perfluorohexyloctane ophthalmic solution) 		Dry eye disease
(evaporative)
Approved & partnered in: USA, Canada, China
 		 

Back of the eye diseases

EyeSol® Product Indication
NOV05
(tacrolimus in EyeSol®, solution) 		Uveitis, non-infectious
Global
IND cleared by FDA
Study started Q1 2026
NQ-Retina
(Peptides/NCEs) 		Diabetic Retinopathy
(multimodal: anti-inflammatory, neuroprotective)
Global
 		IND ready in 2027
NQ-ON
(Peptides/NCEs) 		Undisclosed
(multimodal)
Global
 		IND ready in 2027

For our products we only use highly pure substances and raw materials from qualified manufacturers. We have extensively tested and proven their safety, efficacy and tolerability in close cooperation with the regulatory authorities in Europe and USA, both preclinically and clinically.

Learn more